NASDAQ:GENB Generate Biomedicines Q2 2026 Earnings Results & Report $12.81 +0.29 (+2.31%) As of 01:13 PM Eastern This is a fair market value price provided by Massive. Learn more. Generate Biomedicines missed analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$0.52 versus the -$0.48 consensus estimate, while revenue was $6.31 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market OpensConference Call7:00 AM ET Generate Biomedicines EPS ResultsActual EPS-$0.52Consensus EPS -$0.48Beat/MissMissed by -$0.04One Year Ago EPSN/AGenerate Biomedicines Revenue ResultsActual Revenue$6.31 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Generate Biomedicines Q2 2026 Earnings FAQ Did Generate Biomedicines beat earnings estimates for Q2 2026? Generate Biomedicines (NASDAQ:GENB) reported earnings of -$0.52 per share for Q2 2026, missing the consensus estimate of -$0.48. The report was announced on Thursday, August 6, 2026. What was Generate Biomedicines' revenue for Q2 2026? Generate Biomedicines reported revenue of $6.31 million for Q2 2026. Generate Biomedicines Earnings HeadlinesGenerate Biomedicines Inc (NASDAQ:GENB) Stock Has Consensus Target Price of $26.40October 15 at 2:44 AM | americanbankingnews.comGenerate Biomedicines: Zealand Deal For Obesity Programs May Not Be Quite What It SeemsOctober 14 at 1:13 PM | seekingalpha.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 15 at 1:00 AM | Stansberry Research (Ad)Zealand Pharma, Generate Biomedicines Partner To Develop AI-Designed Metabolic Disease TherapiesOctober 14 at 7:34 AM | rttnews.comGenerate Biomedicines: The Dosing Interval Is The Moat, Not The AlgorithmOctober 14 at 7:34 AM | seekingalpha.comGenerate Biomedicines, Zealand Pharma Report PartnershipOctober 13 at 8:08 PM | marketscreener.comMSee More Generate Biomedicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Generate Biomedicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Generate Biomedicines and other key companies, straight to your email. Email Address About Generate BiomedicinesGenerate Biomedicines (NASDAQ:GENB) is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases. Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules. Generate Biomedicines is advancing a pipeline of investigational medicines, including antibody and other protein therapeutics, with research programs spanning areas such as oncology, immunology and inflammatory diseases. Founded with backing from Flagship Pioneering, Generate Biomedicines operates as a clinical-stage biotechnology company. Its programs remain under research and clinical development, and the company does not currently market approved medicines. Generate Biomedicines is headquartered in the United States and is developing therapies intended for potential use in global healthcare markets.View Generate Biomedicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth Path Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
